Illumina, Inc. (NASDAQ: ILMN) announces that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina’s multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care. SomaLogic’s technologies provide deep insights into protein function, interactions, and modifications, helping to accelerate understanding of complex biology and human health.
Read the full article: Illumina Completes Acquisition of SomaLogic //
Source: https://www.prnewswire.com/news-releases/illumina-completes-acquisition-of-somalogic-302674789.html